- EPZM has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.7 million.
- EPZM has traded 70,192 shares today.
- EPZM is down 3.8% today.
- EPZM was up 25.2% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in EPZM with the Ticky from Trade-Ideas. See the FREE profile for EPZM NOW at Trade-Ideas More details on EPZM: Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). Currently there are 5 analysts that rate Epizyme a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Epizyme has been 340,700 shares per day over the past 30 days. Epizyme has a market cap of $855.0 million and is part of the health care sector and drugs industry. The stock has a beta of 1.25 and a short float of 38.4% with 4.93 days to cover. Shares are up 10% year-to-date as of the close of trading on Monday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.